Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.
Awada H, Abdelmalek M, Cronin T, Baron J, Kashour Z, Azad F, Faisal MS, Faber M, Gravina M, Sung PJ, Green SD, Przespolewski A, Thompson JE, Griffiths EA, Wang ES.
Awada H, et al. Among authors: azad f.
Blood Cancer J. 2023 Sep 4;13(1):131. doi: 10.1038/s41408-023-00910-x.
Blood Cancer J. 2023.
PMID: 37666807
Free PMC article.
No abstract available.